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Muyao Xi* and Lars O. DragstedAbstract
Seaweeds are marine macroalgae, some of which are edible. They are rich in specific dietary fibers and also contain
other characteristic biological constituents. Biological activities have been investigated mainly in animal studies,
while very few results are available from human studies. Biomarkers of food intake (BFIs) specific to seaweed could
play an important role as objective measurements in observational studies and dietary intervention studies. Thus,
the health effects of seaweeds can be explored and understood by discovering and applying BFIs.
This review summarizes studies to identify candidate BFIs of seaweed intake. These BFIs are evaluated by a
structured validation scheme.
Hydroxytrifuhalol A, 7-hydroxyeckol, C-O-C dimer of phloroglucinol, diphloroethol, fucophloroethol,
dioxinodehydroeckol, and/or their glucuronides or sulfate esters which all belong to the phlorotannins are
considered candidate biomarkers for brown seaweed. Fucoxanthinol, the main metabolite of fucoxanthin, is also
regarded as a candidate biomarker for brown seaweed. Further validation will be needed due to the very limited
number of human studies.
Further studies are also needed to identify additional candidate biomarkers, relevant specifically for the red and
green seaweeds, for which no candidate biomarkers emerged from the literature search. Reliable BFIs should also
ideally be found for the whole seaweed food group.
Keywords: Biomarkers of food intake, Food exposure marker, Dietary assessment, Seaweed, MacroalgaeIntroduction
Seaweeds or macroalgae, including species of brown,
red, and green seaweeds, have been consumed as food in
East Asia for a long time, but with more limited use in
Europe and North America, except for the use of certain
constituents as additives [1]. Recent interest in manufac-
turing and consuming high-value food products derived
from seaweeds in Western countries is fueled by their
proposed health benefits as well as by the introduction
of Asian foods. Seaweeds may supply several nutrients
and have been proposed to promote health and counter-
act a wide range of conditions and diseases, such as
obesity, oxidative stress, hypertension, digestive prob-
lems, thrombosis, and even cancer [2–5]. However, this
builds largely on very limited evidence from animal and
in vitro studies. There are also a few trials with seaweeds
or seaweed preparations in humans investigating effects
on blood pressure [5, 6], appetite [7, 8], inflammation
[9], and insulin response [10]. These health effects may© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
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Department of Nutrition, Exercise and Sports, University of Copenhagen,
Copenhagen, Denmarkoriginate from a variety of seaweed compounds, such as
soluble fiber and carotenoids [6, 11–15]. Only one study
has so far shown which compounds can be used as bio-
markers of seaweed intake in overweight or obese sub-
jects. In addition, no study has so far firmly documented
longer-term effects of seaweed intake in human trials.
In order to explore the relationship of seaweed intake
with human health, it is important to measure intake ac-
curately and it is therefore of importance to find specific
compounds related to seaweed intake in general or to
intake of any certain type of seaweed. Intake assessments
in human studies to date largely depend on dietary as-
sessment instruments such as food frequency question-
naires (FFQ) or 24-h recalls (R24h). These instruments
are prone to recall bias and systematic errors [16]. Lack
of compliance is also common in dietary intervention
studies. Thus, it is difficult to evaluate the relationship
between health effects and seaweed intake. Well-
validated biomarkers of food intake (BFIs) may provide
more objective estimates of actual intake.
The objectives of this review are (1) to summarize in-
formation from the scientific literature related tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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as, candidate biomarkers for seaweed consumption [16]
and (2) to provide systematic validation of the candidate
BFIs based on recent methodology [17].
Materials and methods
Defining the food group
Seaweeds are not well-defined in biological terms but
cover largely the macroalgae. The macroalgae contain
species belonging to several different phyla consisting of
red, green, or brown algae and in some cases are consid-
ered to include also the prokaryotic photosynthetic
cyanobacteria. Within the food group of seaweeds, there
is a corresponding subdivision into three food sub-
groups, the red, brown, and green seaweeds, each with a
large number of species. Although there are differences
within and between these 3 subgroups of seaweed, it is
considered of interest to find candidate biomarkers of
the overall seaweed group as well as for each subgroup.
Within each subgroup, there are many species that are
likely to vary considerably in composition; however, the
present review will not emphasize the detail of species
or of varieties within species because little is known at
this level of detail.
Primary literature search for relevant BFIs for seaweed
intake
Original research papers were searched within three da-
tabases (Scopus, PubMed, and the ISI Web of Know-
ledge). The search made use of combinations of several
search terms with inclusion and exclusion criteria as
keywords, as described for the BFIRev literature search
procedure [16]: (biomarker* OR marker* OR metabolite*
OR biokinetics OR biotransformation OR pharmacokin-
etics OR bioavailability OR ADME) AND (intake OR
meal OR diet OR ingestion OR consumption OR eating
OR drink* OR administration) AND (human* OR men
OR women OR patient* OR volunteer* OR participant*)
AND (urine OR plasma OR blood OR serum OR excre-
tion OR hair OR toenail OR feces OR fecal water) AND
(seaweed OR macroalgae). The field of each database
used as default is [Article Title/ Abstract/ Keywords] for
Scopus, [All Fields] for PubMed, and [Topic] for ISI
Web of Science. The search for papers on seaweed in-
take biomarkers was covering all papers published up
until March 2019 but was restricted to papers in the
English or Chinese language. Additional papers were ac-
quired from reference lists of included papers after filter-
ing and from reviews, books, or online databases
(Google Scholar). Exclusion criteria avoided papers deal-
ing only with effects of ingested seaweed on diabetes
and other diseases, plasma lipids, organ damage, anti-
oxidation, and other articles not relevant to intake bio-
markers; animal studies were also largely excludedunless they contain information on unique seaweed-
derived compounds. Papers on contaminants and min-
eral contents of seaweed were also excluded from the
search.
Secondary search—evaluation of putative BFIs
After identification of potential candidate BFIs from
the primary literature search, a second search step
was performed to evaluate the specificity of each pu-
tative BFI for seaweed intake. The second search was
carried out by replacing (seaweed OR macroalgae)
with (“the name and synonyms of the potential candi-
date biomarker” OR “the name and synonyms of po-
tential candidate biomarker class”). In addition to the
online databases listed above, hmdb [18] and foodb
[19] were searched for each putative BFI in order to
ascertain that they have not been measured previously
in other foods. The full list of putative BFIs is shown
in Table 1. Plausibility of the BFIs, i.e., the evaluation
of whether the putative marker compound is likely to
be uniquely present in seaweeds, was decided based
on the secondary search; the final list of plausible
BFIs are shown as the top 7 items of Table 2.
Validation criteria of candidate BFIs
The candidate BFIs were validated according to a set of
criteria published recently [17]. There are 8 topics in this
validation system (Additional file 1: Text S1) relating to
aspects of analytical performance, applicability in nutri-
tion research, and various aspects of biological validity,
which were answered for each candidate BFI in Table 3.
Results
The original search process retrieved 364 research pa-
pers, of which 290 remained after excluding duplicates.
Subsequently, the number decreased to 21 eligible pa-
pers after screening titles and abstracts. The other 269
papers were eliminated because they were not relevant
in relation to seaweed BFIs, mainly because they were
not concerned with seaweed constituents or mentioned
only contents of common nutrients in seaweeds. The
twenty-one remaining eligible full-text articles were eval-
uated for relevant content about BFIs. The reference lists
were additionally checked to acquire more relevant pa-
pers. As a result of this selection process, 8 papers were
identified from the database search and 1 paper from
reference lists for further review (Fig. 1 and Additional
file 1: Table S1). The relevant information from the se-
lected 9 papers is extracted into Table 1. The studies in-
cluded four single oral dose intervention studies, one
unblinded short-term and one unblinded long-term
intervention study; one short-term, double-blind,
placebo-controlled and one short-term open-label paral-
lel study; and one long-term randomized, double-blind,
Table 1 List of studies reporting putative biomarkers for brown seaweed consumption
Dietary factor Study
design
Number and age of
subjects
Analytical
method
Sample
type
Discriminating
metabolites
Primary
reference(s)
Brown seaweed (food-
grade seaweed
capsule) 400 mg
containing 101.89 mg
polyphenol
Single oral dose
intervention study with no
control group
12 women and 12 men
(aged 18–65 years)
Plasma
((RP)-HPLC-
DAD), urine
(RP-HPLC-
DAD and
HPLC-MS)
Hydrolyzed
urine
Hydroxytrifuhalol A, 7-
hydroxyeckol, C-O-C dimer
of phloroglucinol
[20]
Hydrolyzed
plasma
Data not shown in the
paper
Brown algae
(Ascophyllum
nodosum) capsule 400
mg containing 107.3
mg phlorotannin
A 24-week randomized,
double-blind, placebo-
controlled crossover trial
39 men and 41 women
(aged 30–65 years)
UHPLC-HR-
MS
HPLC-DAD
Urine Pyrogallol/phloroglucinol
sulfate, hydroxytrifurahol A-
glucuronide, dioxinodehy-
droeckol glucuronide, C-O-C
dimer of phloroglucinol sul-
fate, diphlorethol sulfate,
fucophloroethol
glucuronide
[21]
Plasma No markers found
10 ml kombu extract
containing 31 mg
fucoxanthin
Single oral dose
intervention study with no
control group
10 males and 8 females
(aged 22–63 years)
HPLC-UV-
VIS
Plasma Fucoxanthinol [22]
Stir-fried wakame
containing 6.1 mg
fucoxanthin
1 week dietary intervention
study with no control group
3 women and 2men
(aged 30–50 years)
(SPE)-HPLC-
DAD
Plasma Fucoxanthinol [23]
Astaxanthin from a
supercritical CO2
extract of
Haematococcus
pluvialis (green
seaweed) as a softgel
capsule (0, 2, 8 mg)
A 8-week double-blind,
placebo-controlled study
42 females
(aged 20–23 years)
RP-HPLC-
DAD
Plasma Astaxanthin [24]
Haematococcus
pluvialis extract.
12 soft capsules, each
containing 4 mg of
astaxanthin, total 48
mg
Single oral dose
intervention study with no
control group. Two females
and five non-smoking males
received the capsules 2 h in
advance of a meal, the
others took them right after
the meal.
15 males (7 smokers)
and 5 females (aged
18–60 years)
HPLC-UV-
VIS
Serum Astaxanthin [25]
Green alga + lipid to
be formulation
contained 40 mg
astaxanthin
Open parallel design
dividing into 4 groups on
average for 4 days
32 males (aged
20–46 years)
HPLC-VIS Plasma Astaxanthin [26]
100 mg astaxanthin
with olive oil and
cereals for 3 days
Single dose intervention
study with no control group
3 males (aged
37–43 years)
HPLC-UV-
VIS
Plasma Astaxanthin [27]
Average 50 sheets of
nori (average 200 g β-
carotene) for 5 months
Sequential intervention One 22-year-old
female
/ Serum β-carotene [28]
Abbreviations: DAD diode array detector, HPLC high-performance liquid chromatography, MS mass spectrometry, RP reverse phase, SPE solid-phase extraction,
UHPLC-HR-MS ultra-high-performance liquid chromatography–high-resolution mass spectrometry, UV-VIS ultraviolet-visible spectroscopy
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tional studies were found to use BFIs.
In a secondary search, we carried out a web-database
check and a literature search for compounds from Table
1 to evaluate whether these compounds are specific to
seaweed or might exist in other foods. Non-specific bio-
markers are listed as the last 6 items in Table 2, includ-
ing relevant exclusion criteria. Additional file 1: Table S1
lists the source of primary literature and information
collected from these studies.Hydroxytrifuhalol A, 7-hydroxyeckol, C-O-C dimer of
phloroglucinol, diphloroethol, fucophloroethol, dioxino-
dehydroeckol, and/or their glucuronides or sulfate esters
(Additional file 1: Figure S1) were selected as candidate
BFIs for brown seaweed because of their apparent speci-
ficity and their suitable postprandial kinetics [20, 21].
Fucoxanthinol, a metabolite of fucoxanthin, has also
been found in plasma from a study after only a single
oral dose of brown seaweed, making it interesting also as
a candidate short-term biomarker [22].
Table 2 Summary of the putative biomarkers of seaweed intake, including reasons for inclusion or exclusion from the final list of
candidate biomarkers
Food item Metabolites Biofluid locations Reason for inclusion and exclusion Selected for
further systematic
validation as BFIs
Brown seaweed Hydroxytrifuhalol A Hydrolyzed urine Specificity and suitable
post-prandial kinetics
Yes
Brown seaweed 7-Hydroxyeckol Hydrolyzed urine Specificity and suitable
post-prandial kinetics
Yes
Brown seaweed C-O-C dimer of phloroglucinol Hydrolyzed urine Specificity and suitable
post-prandial kinetics
Yes
Brown seaweed Dioxinodehydroeckol glucuronide Urine Specificity and suitable
post-prandial kinetics
Yes
Brown seaweed Diphlorethol sulfate Urine Specificity and suitable
post-prandial kinetics
Yes
Brown seaweed Fucophloroethol
glucuronide
Urine Specificity and suitable
postprandial kinetics
Yes
Brown seaweed Fucoxanthinol Plasma Quite specific, existing in many
other marine foods but much lower
than that in brown seaweeds
Yes
Brown seaweed Pyrogallol sulfate Urine Unspecific, also a metabolite found
after intake of tea, mango, berry fruits,
nuts and red wine.
No
Brown seaweed Phloroglucinol sulfate Urine Unspecific, also a metabolite found
after intake of grape. Phloroglucinol
is also a drug.
No
Brown seaweed Fucoxanthin None Only reported in seaweed and at low
levels in some crustaceans, not yet
detected in human plasma
No
Green seaweed Astaxanthin Serum Unspecific, existing in many
other marine foods
No
Green seaweed Astaxanthin Plasma Unspecific, existing in many
other marine foods
No
Red seaweed β-carotene Serum Unspecific, existing in many
fruits and vegetables
No
Table 3 Overview of the current level of validation of the candidate biomarkers of seaweed intake
Food item Metabolites Biofluid
locations
Questionsa
1 2 3 4 5 6 7 8
Brown seaweed Hydroxytrifuhalol A Hydrolyzed urine Y U Y U U U U U
Brown seaweed 7-Hydroxyeckol Hydrolyzed urine Y U Y U U U U U
Brown seaweed C-O-C dimer of
phloroglucinol
Hydrolyzed urine Y U Y U U U U U
Brown seaweed Dioxinodehydroeckol
glucuronide
Urine Y U Y U U U U U
Brown seaweed Diphlorethol sulfate Urine Y U Y U U U U U
Brown seaweed Fucophloroethol glucuronide Urine Y U Y U U U U U
Brown seaweed Fucoxanthinol Plasma Y U Y U U U U U
aThe criteria are 1, plausibility; 2, dose response; 3, time response; 4, robustness; 5, reliability; 6, stability; 7, analytical performance; 8, reproducibility. The full text
of questions Q1–Q8 is reported in Additional file 1: Text S1. Possible answers are Y (yes, the criterion is fulfilled for at least some use of the biomarker), N (no, the
criterion has been investigated but it was not fulfilled), or U (uncertain, the criterion has not been verified or data is not available). The questions are based on the
criteria outlined by Dragsted et al. [17]
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Fig. 1 Flow diagram of systematic literature search according to the BFIRev methodology. The three databases PubMed, SCOPUS, and Web of
Science were searched as outlined in the “Methods” section. After duplicate removal, titles were screened to select papers for further screening of
abstracts. Abstracts were screened for selecting full-text papers, and reference lists of the selected papers were screened for additional relevant
papers. During the process, most titles and abstracts were excluded for reasons outlined in the side boxes. A total of nine relevant references
were included in the review
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they are known to be present in seaweed. These
include fucoxanthin [22, 23], siphonaxanthin [29],
astaxanthin [24, 25, 27, 30], and beta-carotene [28].
The first two of these have not so far been observed
in human blood and therefore cannot be validated.
The last two are abundant in many other foods and
are therefore not even plausible as specific BFIs for
seaweed. Another 2 markers (pyrogallol sulfate [31],
phloroglucinol sulfate [32]) were excluded from
Table 2 since they are also metabolites of many
other foods, and phloroglucinol is also potentially
used as a drug [33].
Further experimental work needs to be done to find
BFIs for intake of green and red seaweed while the 7
compounds in Table 3 may also be considered as
candidate BFIs for seaweed in general, either alone or in
combination. While these compounds are candidate BFIs
for intake of brown seaweed, their specificity to the
brown seaweeds is not well documented and they may
potentially also be useful as BFIs to assess the intake of
the whole seaweed subgroup of marine foods. This
would need further studies of the presence of these
compounds in red or green seaweeds.The seven candidate BFIs were assessed by the
validation criteria published recently [17] as discussed
below and shown in the legend of Table 3 and in
Additional file 1: Text S1. The seven compounds are
promising BFI candidates meeting several of the
published validation criteria; however, we still lack
information on their robustness, e.g., evidence from
cross-sectional studies that these compounds are only
observed after intake of seaweed and not after any
other foods. In some cases, combinations of
unspecific markers, which each overlap with a few
other foods may provide very good specificity [34] as
qualitative markers (e.g., seaweed intake yes/no) and
such unspecific markers are therefore reasonable to
retain even if the single compounds fail validation.
The quantitative dose-response relationship of BFIs in
human samples will also be needed to provide
evidence for their use in quantification of seaweed
intake. Currently, none of the candidate BFIs is fully
validated for estimation of seaweed intake by all the
validation criteria. Therefore, more experimental and
observational studies need to be done on this food
group to validate the current candidate biomarkers or
their combinations.
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Seaweeds have an ancient history as foods in certain
regions and cuisines and extraction of hydrocolloids from
seaweed as food additives dates back several centuries
[35]. Seaweed consumption has been investigated scientif-
ically only over the past 20–30 years, primarily focusing
on chemical constituents of potential benefit to food
science or for their health effects or risk to consumers.
Many seaweed studies in the area of food chemistry focus
on compounds, which have potential health benefits, such
as polyphenols [20] or they are concerned with the nutri-
tional compounds in seaweed, such as iodine [36], or with
contaminants, such as arsenic [37]. The current review
has evaluated potential seaweed BFIs; components used as
food additives, nutrients, and contaminants were excluded
as BFIs because they are not expected to be specific to
seaweeds.
Brown seaweed biomarkers
Phlorotannins
Brown seaweeds have a high content of polyphenolic com-
pounds. The concentrations of phenols in brown seaweed
species are higher than in red or green seaweeds [38, 39]
or in other marine plants [40]. The main group of
polyphenols in the marine brown seaweeds is phlorotan-
nins, a type of phenolic constituents common to seaweeds
and mainly found in brown species such as Cystoseira
nodicaulis, Cystoseira tamariscigolia, and Fucus spiralia
[41–46]. Phlorotannins are a highly diverse group, com-
prising a series of phloroglucinol derivatives [45]. There
are currently very few human studies on the metabolism
and bioavailability of seaweed phlorotannins. Therefore,
there is a lack of human studies to compare the bioavail-
ability of polyphenols between different seaweed species.
Corona et al. [20] found that some oligomeric phlorotan-
nins can be detected in seaweed polyphenol extract as well
as in extracts which have been digested and fermented
in vitro. The raw polyphenol extracts were provided as
capsules to 24 volunteers while collecting blood and urine
samples up till 24 h, respectively [20]. There are generally
two concentration peaks both in plasma and urine, in
which the first one is at 1–2 h in plasma as well as in urine
and the second one is at 4–8 h in plasma and 8–24 h in
urine following a polyphenol-rich meal [47]. In this study,
the majority of phlorotannin metabolites appeared at 6–
24 h, indicating initial small intestinal absorption of less-
complex polyphenols and subsequent large intestinal
absorption after fermentation of more-complex polyphe-
nols into smaller molecules; enterohepatic circulation may
also wholly or partially explain the observation. These
polyphenols could possibly be seen as potential BFIs for
recent seaweed intake. A range of phlorotannin metabo-
lites were identified in plasma and urine separated by
HPLC, especially hydroxytrifuhalol A, 7-hydroxyeckol,and the C-O-C dimer of phloroglucinol, identified only in
urine; the structures were further confirmed by LC-MS/
MS in the negative ionization mode, thereby confirming
also some of the pathways of gut microbial phlorotannin
degradation [20]. In addition, two unknown pseudomole-
cular ions (m/z 289 and 377) corresponded to metabolites
present both in urine after intake of extracts and in vitro
after simulated GI digestion and fermentation of extracts.
Therefore, these two ions can be regarded as clues for
further identifications [20]. Another study [21] also re-
ported that the phloroglucinol derivatives, pyrogallol and
phloroglucinol sulfates, dioxinodehydroeckol glucuronide,
diphlorethol sulfate, and fucophloroethol glucuronide, can
be found in human urine after seaweed intake. Pyrogallol
and phloroglucinol sulfates would not be considered as
plausible biomarkers of seaweed, although they can be
measured in urine after seaweed intake. Pyrogallol sulfate
is a common microbial phenolic metabolite, which is also
found in both urine and plasma after intake of tea, mango,
berry fruits, nuts, and red wine [48–52]. Therefore, it is
not a specific metabolite after seaweed consumption.
Phloroglucinol sulfate is also a metabolite after intake of
several other foods, such as grape [32]. It is reported as a
drug as well [33]. Thus, phloroglucinol sulfate is not spe-
cific enough to be regarded as a biomarker of seaweed in-
take. Figure 2 shows that seaweed phlorotannin
polyphenols may undergo gastric digestion, small intes-
tinal deglucosylation, and absorption to be metabolized by
phase II enzymes in line with other plant polyphenols.
Some phlorotannin metabolites can be detected in the
plasma and urine between 0 and 8 h after seaweed intake.
Unabsorbed phlorotannins will reach the large intestine
where enzymes of the gut microbiota may play an import-
ant role to metabolize phlorotannins into smaller
phloroglucinol-related compounds, leading to a second
phase of absorption of the majority of metabolites with
peaks at 6–24 h in plasma and excretion between 8 and
24 h in urine. In plasma and urine samples, which have
not been treated with glucuronidase or sulfatase, a num-
ber of the phase II metabolites can appear [20, 47, 54]. In
the study by Corona et al., there were substantial differ-
ences among volunteers in their pattern and extent of
phlorotannin metabolism [20]. The total level of phloro-
tannins and their metabolites ranged from 0.01 to 7.8 μg/
ml and from 0.15 to 33.5 μg/ml quantified as phlorogluci-
nol equivalents in urine and plasma, respectively [20],
while the range extended from 0.13 to 522.09 μg/ml
quantified as phloroglucinol equivalents in urine in an-
other study [21]. The large inter-individual differences
have been attributed to variation in the microbiota com-
position in the colon and to differences in expression of
phase II metabolizing enzymes [47, 55], suggesting large
inter-individual variation in metabolite kinetics and,
consequently, in their potential usefulness as BFIs for
Fig. 2 Summary of seaweed polyphenol ADME. The main factors affecting absorption, metabolism, distribution, and excretion of seaweed
polyphenols in different segments of the gastrointestinal tract are listed in each box. Redrawn based on [53]
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additional metabolites are formed but not yet identified or
what specific microbial functionality is needed to degrade
these particular compounds.
One of the papers has measured some of the metabo-
lites in plasma (with the data not shown) [20] while the
other paper did not observe any polyphenol metabolites in
the plasma metabolome [21]. Both studies provided the
postprandial time-course kinetics of measured metabolites
in urine or plasma without including dose-response rela-
tionships. Some additional factors [56] may also affect
ADME and need to be taken into consideration, including
the effect of the food matrix, of cooking, or/and of pro-
cessing on phlorotannin contents. Another consideration
is the lack of commercially available standards for the
phlorotannin-derived candidate BFIs. Phlorotannins may
be quantified as phloroglucinol equivalents using phloro-
glucinol as standard in a colorimetric assay [57], but the
method is imprecise and may not provide the same color
reaction for conjugated metabolites. Because hydroxytrifu-
halol A, 7-hydroxyeckol, dioxinodehydroeckol glucuro-
nide, diphlorethol sulfate, fucophloroethol glucuronide,
and C-O-C dimer of phloroglucinol are phlorotannin olig-
omers, most of them are metabolized in the colon by the
microbiota, possibly into smaller phenolics. More work
still needs to be done to identify these metabolites and to
validate their specificity as seaweed BFIs.
Fucoxanthin and fucoxanthinol
Brown seaweeds are the exclusive source of fucoxanthin
production in the food chain. Fucoxanthin, the main ca-
rotenoid in brown seaweeds, acts as a component of the
light-harvesting complex for photosynthesis and photo-
protection, which colors brown algae and the compound
does not exist in red or green algae [58–61].
The fucoxanthin content of various brown seaweeds has
been summarized based on several studies showing a re-
ported interval of 0.3–3.7 mg fucoxanthin per gram dry
weight of algae [23, 62]. Fucoxanthin and its metabolites
are also present in many species of marine mollusks, such
as clams (e.g., Corbicula fluminea), mussels (e.g., Mytilusedulis), chitons (e.g., Chiton magnificus), sea snails (Halio-
tis spp.), and possibly other bivalves because their main
food source consists of seaweeds and diatoms [63–66]; the
metabolites have been identified based on data from spec-
troscopic and chromatographic analyses. The specificity of
fucoxanthin or its metabolite, fucoxanthinol, as intake bio-
markers specific for consumption of seaweeds therefore
needs some additional consideration; some studies show
that the concentration of fucoxanthin ranges from 0.0045
to 0.0795mg per 100 g edible part of marine mollusks,
which equals 0.27–6.59 μg per gram dry weight [65, 67].
Therefore, the content of fucoxanthin in seaweed is much
higher than that in marine mollusks. So if brown seaweeds
are part of the diet, they are the more important dietary
source of fucoxanthin compared to other marine foods.
However, fucoxanthin cannot be detected in plasma, even
after brown seaweed consumption [22, 23], most likely be-
cause it is extensively hydrolyzed into fucoxanthinol.
Fucoxanthinol, the hydrolyzed, deacetylated metab-
olite of fucoxanthin, has been detected in human
plasma by HPLC. The compound has also been found
in the intestinal tract or intestinal cells. Two studies
[22, 23] have shown that the concentration of fucox-
anthinol in human plasma is around 0.8 (SD 0.4) nM
after the final day of a 1-week seaweed intervention
providing 6.1 mg fucoxanthin from 6 g dried wakame
per day but as much as 44.2 nM 4 h after a meal con-
taining 31 mg fucoxanthin from 10 ml of kombu ex-
tract. According to these 2 human studies, we may
conclude that the concentration of fucoxanthinol in
plasma was associated with the duration of the period
of intake and the concentration of fucoxanthin pro-
vided in the food. A review [63] illustrated that a
similar metabolic pathway for fucoxanthin exists in
marine animals, leading to the formation of fucox-
anthinol, although there may be minor differences
between species. Fucoxanthinol in particular was
present in tissues of some marine mollusks as an
intermediate metabolite of fucoxanthin. In general,
animals such as clams cannot synthesize carotenoids
by themselves de novo, leaving two possibilities. One
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other is that partial modification of ingested caroten-
oids takes place through metabolic reactions within
the clams. Some studies also report that fucoxanthi-
nol can be extracted from the edible part of marine
mollusks ranging from 0.09 to 15.52 μg per gram dry
weight [64, 65, 67]. Thus, the concentration in marine
mollusks is much higher than that in human plasma.
However, due to the scarcity of data, we still need
further studies to evaluate whether this metabolite
could be a candidate biomarker for brown seaweed.
Maoka et al. [64] also concluded that the major food
source of bivalves (clams) are diatoms (unicellular
algae), which would include several species that
produce fucoxanthin. Fucoxanthin can be further me-
tabolized into halocynthiaxanthin 3’-acetate, mytiox-
anthin, crassostreaxanthin A, and amarouciaxanthin A
in bivalves. Amarouciaxanthin A has also been de-
tected as a hepatic metabolite in mice [68]. However,
there are no human studies reporting any of these
metabolites. It is therefore important to consider the
relative importance of seaweed and other seafoods
(e.g., shellfish) to the intake of marine xanthophylls
and their metabolites. More human studies will be
needed in order to find more reliable biomarkers to
discriminate between the marine plants and animals
taking into account that they may have unique meta-
bolic pathways, e.g., for fucoxanthin.
Fucoxanthin is deacetylated into fucoxanthinol by hu-
man intestinal epithelial cells and in the digestive tract of
mice by lipase and esterase before absorption into the
blood circulation [69]. Asai and coworkers showed that
fucoxanthinol could be detected in human plasma after 1
week with brown seaweed intake. They conducted a diet-
ary intervention in five healthy subjects with stir-fried
wakame (~1mg fucoxanthin/day), a product consisting of
the brown seaweed, Undaria pinnatifida. Fucoxanthinol
could not be detected at baseline after a 1-week wash-out
period without seaweed intake [23]. A mouse study also
indicated that fucoxanthinol did not accumulate in any
tissue or plasma since fasting levels observed after 1 week
of feeding was similar to the background level measured
in control mice; despite this finding, the authors con-
cluded that accumulation was taking place in heart muscle
but no statistical evidence was presented to substantiate
this claim [70]. Half-lives of 3–7 h were observed for
fucoxanthinol in most organs with bimodal kinetics and
no residual measurable concentration at 24 h after dosing,
except possibly for the heart [70]. It has been shown that
fucoxanthinol is detectable in plasma 4 h after the admin-
istration of a single dose of seaweed extract, but that fuco-
xanthin is not [22]. The possible reasons are that some
components in the seaweed matrix, such as dietary fiber,
may inhibit the intestinal absorption of fucoxanthin [66]or that the analytical method was not sufficiently sensitive.
Fucoxanthinol could be detected after 24 administrations
of kombu, a dried seaweed product consisting mainly of
Laminariacea, a group of brown seaweeds. Further short-
term kinetic studies after fucoxanthin intake in humans
are needed in order to evaluate the dose-response kinetics
and potential accumulation of fucoxanthinol after a single
intake. Interestingly, both human studies mentioned de-
tection of the cis-isomer of fucoxanthinol in plasma after
intake of seaweed, but the specific structure was actually
not verified.
The bioavailability of fucoxanthinol in humans seems to
be lower than that of other types of carotenoids such as
lutein, β-carotene, and astaxanthin. In Hashimoto’s study
[22], intakes of fucoxanthin around 47 μM resulted in an
AUC of fucoxanthinol of below 0.6 μM × h; in compari-
son, 30% lower intakes of β-carotene, lutein, or astax-
anthin resulted in AUCs of 13.6 μM × h, 42.8 μM × h, and
2.26 μM × h, respectively, i.e., considerably higher than for
fucoxanthinol [26, 54]. Bioavailability of fucoxanthinol in
mouse and rat studies is also lower but not significantly
so, compared to the other carotenoids mentioned above
[70, 71]. Hashimoto et al. found that fucoxanthinol has a
much higher bioavailability in human subjects compared
with mice [70], similar to what is observed for other carot-
enoids [26, 54, 71]. After a single oral dose of 10ml sea-
weed extract in 15 human volunteers (only 15% of the
dose previously administrated to mice) Cmax and AUC(∞)
were approximately 33% and 46% of those observed in
mice, respectively. However, the average elimination half-
life of fucoxanthinol excretion was 7 h in humans (4.5 h in
mice) and its concentration in urine at 24 h was 7.6 nM
(8.2 nM in mice) [22, 70]. The low apparent absorption of
fucoxanthin compared to fucoxanthinol in humans may
therefore be caused mainly by a higher biotransformation
rate into fucoxanthinol.
Some researchers have shown that the food matrix
plays a less important role for fucoxanthin than for
other carotenoids, but still depending somewhat on
fat contents. The lower lipophilicity may limit the
intestinal emulsification of fucoxanthinol compared
with other carotenoids [23, 72, 73]. Fucoxanthin
from seaweed seems to have poor bioaccessibility
with a relatively low incorporation of the compound
into micelles, explaining its low concentration in hu-
man plasma. Deacetylation of fucoxanthin may be
caused by enzymes secreted in the human intestines
or present within the brush border of the epithelial
cells so that biotransformation in the upper gastro-
intestinal tract is the major cause of the fast appear-
ing peak of fucoxanthinol as well as the very low
extent of fucoxanthin absorption. The human en-
zyme(s) responsible for this degradation still need to
be identified.
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cis-isomer of fucoxanthinol, but did not provide a detailed
identification. Sugawara and coworkers also reported that
the metabolite of fucoxanthin observed by HPLC-MS is
the cis-isomer of fucoxanthinol after incubating with dif-
ferentiated caco-2 human intestinal cells and plasma from
mice [69]. There are also several studies reporting that the
cis-isomer of fucoxanthinol and halocynthiaxanthin are
the metabolites of fucoxanthin in marine animals [74, 75].
However, the latter metabolite has not yet been found in
human samples. In studies with several brown seaweeds,
the all-trans form was found to be by far more abundant
than the cis-forms (9-cis and 13-cis), so it seems most
likely that the all-trans form is the usual configuration
found in brown seaweeds [76].
Green seaweed intake biomarkers
Astaxanthin
Green seaweeds, such as Haematococcus, are the richest
natural source of the xanthophyll, astaxanthin (3,3′-dihy-
droxy-β, β′-carotene-4,4′-dione) [77]. Astaxanthin is
found in seaweed as esters where its hydroxyl groups are
acylated with fatty acids, while only free forms can be de-
tected in human serum after ingestion; this would indicate
that hydrolysis takes place before absorption [25]. Free
astaxanthin was found in the gastrointestinal tract (GIT),
skin, and blood of humans [24, 25, 78]. Carotenoid bioac-
cessibility is quite variable among humans and more stud-
ies are needed on genetic and acquired variability in
carotenoid absorption [79], including the efficiency and
inter-individual variability of astaxanthin ester hydrolysis
in humans GIT.
Although astaxanthin has been found in blood after
intake of green seaweed in human studies [24–26], it is
found also in many marine animals [53, 77, 80], due to
accumulation in the food chain as a natural lipophilic
compound. There are high amounts in the carapace of
crustaceans and in the flesh of salmon [24]. Astaxanthin
is also present in certain food colorants, e.g., E161.
Sources other than seafood are therefore also possible in
the diet of humans. In a review of astaxanthin contents
in aquatic organisms, levels of 6–25mg/kg wet weight
were found in trout while the levels in microorganisms
were 0.001–3.8% of dry weight (10–3800mg/kg) [80],
highest in microalgae. In macroalgae, a high level (0.02%
of dry weight, 200mg/kg) has been reported in Ulva
intestinalis, a species commonly eaten under the name
of green anori while comparable levels in dried shrimp
were 0.12% (1200 mg/kg). Within the seafoods, crusta-
ceans and fish would therefore contribute much more
than seaweeds to the levels in humans in most diets.
While further studies would be needed to compare the
bioavailability of astaxanthin from these different
sources, the compound will not be considered furtherhere as a biomarker of seaweed intake since astaxanthin
is not likely to be robust in a population study.
Red seaweed intake biomarkers
Red seaweed is another group of seaweeds including sev-
eral edible species, including dulse (Palmaria palmata)
from the North Atlantic Ocean and Japanese nori (Pyropia
sp.) from the Pacific. They contain a variety of pigments,
including phycoerythrins and carotenoids. Phycoerythrins
harvest light energy as part of a protein complex channel-
ing the energy to chlorophyll. No human studies have
been performed with red algae to investigate the metabol-
ism of phycoerythrins or their potential use as biomarkers
of red seaweed intake.
β-carotene
Nori contains β-carotene and the content in a sheet of
nori is the same as that in 10 oranges or in 50 g of car-
rot. In our search, only one paper described a human
study that focused on red seaweed intake. The concen-
tration of serum β-carotene was much higher than nor-
mal levels after around 5 months of nori intake [28].
However, many fruits and vegetables are rich in β-
carotene. Mango, carrot, and green vegetables are all
rich in β-carotene [81–84]. Therefore, β-carotene cannot
be considered as a candidate biomarker of red seaweed
intake in populations ingesting other rich sources of the
compound and β-carotene is therefore not considered
further here.
Validation of candidate BFIs
There are totally 7 compounds which can be considered
for validation. All of these candidate BFIs for brown sea-
weeds should be validated according to the procedure
previously outlined [17].
Phlorotannins
The metabolites of phlorotannins, hydroxytrifuhalol A,
7-hydroxyeckol, C-O-C dimer of phloroglucinol, and
phlorotannin-derived candidate biomarkers were de-
tected in hydrolyzed urine in one single-dose interven-
tion without a control group [20]; in addition, some
unknown metabolites from an in vitro study were men-
tioned in this paper. The blood samples were collected
at nine time points with the plasma concentration of
phlorotannins varying from 0.011 to 7.757 μg/ml; urine
samples were collected at three time points with a con-
centration of phlorotannin ranging from 0.15 to
33.52 μg/ml. Collected urine and plasma samples were
stored at − 80 °C until analysis after one and a half years,
indicating that the compounds may be stable under
these conditions so that measurements are likely to be
reliable and feasible; however, multiple measurements of
stored samples are needed for a firm conclusion on
Xi and Dragsted Genes & Nutrition           (2019) 14:24 Page 10 of 13stability and measurement reliability for the phlorotan-
nin candidate BFIs.
The metabolites of phlorotannins, hydroxytrifurahol A-
glucuronide, dioxinodehydroeckol glucuronide, C-O-C
dimer of phloroglucinol sulfate, diphlorethol sulfate, and
fucophloroethol glucuronide were detected in urine in
one crossover study [21] where 24-h urine samples were
collected at each time point (weeks 0, 8, 16, and 24) and
the concentration of phlorotannin ranged from 0.13 to
522.09 μg/ml. In addition, some unknown or less-
significant metabolites in urine were also mentioned in
this paper. The collected urine and plasma samples were
stored at − 80 °C until the end of the intervention, i.e., for
at least 6months, revealing that the compounds may be
stable, but this needs more thorough investigation.
Thus, the phlorotannin candidate biomarkers have short
half-lives and may therefore be good short-term markers
based on the two human studies. Hydroxytrifuhalol A and
C-O-C dimer of phloroglucinol were detected by various
types of studies in normal-weight as well as overweight
volunteers, indicating that these two compounds are not
affected by overweight. Additional studies are still re-
quired to verify the stability of these compounds.
The information available for comparing various analyt-
ical methods is quite limited so it is difficult to assess the
analytical quality of marker analyses in human samples.
Additional observational studies are needed to evaluate
robustness and dose response. Ideally, a meal study with
different levels would be needed for dose-response assess-
ment. Additional studies with other intake assessment
methods would also be needed to evaluate reliability of
the candidate BFIs. In addition, human studies with sev-
eral different species of (brown) seaweeds, with cooked
seaweed, and with other seaweed preparations are needed
to evaluate the influence of food processing on the
phlorotannin-derived BFIs. Both existing studies have re-
ported on the presence of the conjugated or enzymatically
de-conjugated phlorotannin metabolites in urine. Al-
though phloroglucinol was used as standard in the two
studies, quantitative analysis of these compounds would
require availability of isotope-labelled standards. Thus,
there are no studies available to compare the performance
of the analytical methods or to conclude on analytical
variability, including accuracy, precision, sensitivity, and
specificity of the measurements. Additional studies there-
fore need to be performed to fully validate the poly-
phenolic biomarkers of brown seaweed intake.
Fucoxanthinol
Fucoxanthinol has been detected in plasma after brown
seaweed extract intake in human studies, indicating that it
is possible to be considered as a candidate biomarker for
estimating intake of seaweeds. Although fucoxanthinol
can be detected in some marine mollusks and theconcentration there is higher than that in human plasma,
the parent compound (fucoxanthin) in brown seaweeds is
much higher than that in marine mollusks. Therefore,
fucoxanthinol can still be considered a candidate bio-
marker of brown seaweed intake. Two human studies
have reported on fucoxanthinol after brown seaweed in-
take; one is an oral single-dose study, the other is a 1-
week dietary intervention study. The plasma samples were
collected at seven time points with the maximum concen-
tration, 44.2 nM, at 4 h after intake of 10ml kombu ex-
tract containing 31mg fucoxanthin. Thus, fucoxanthinol
has a known time response following a single meal study
in humans. Additional observational studies and a meal
study with different levels are needed to evaluate robust-
ness and dose-response assessment. Collected plasma
samples were stored at − 80 °C until analysis in human
studies, but no information was provided on the storage
time before analysis. Further study of the reliability of
fucoxanthinol as a biomarker is needed to validate it. Sta-
bility, analytical performance, and reproducibility are also
still required to fully validate fucoxanthinol as a biomarker
of brown seaweed intake.Conclusion
Only a few potentially specific compounds have been
found in urine or plasma after intake of seaweeds in hu-
man studies, so the number of potential BFIs is small for
the groups of brown seaweeds and for the whole group.
The few compounds selected as candidate BFIs are
hydroxytrifuhalol A, 7-hydroxyeckol, C-O-C dimer of
phloroglucinol, diphloroethol, fucophloroethol, dioxino-
dehydroeckol, and/or their glucuronides or sulfate esters,
as well as fucoxanthinol. However, more information is
required for their validation, including observational
studies to verify robustness, and further meal studies
and studies on stability and other aspects of analytical
performance are also needed to confirm whether these
compounds are specific and feasible for assessing only
brown seaweed consumption or possibly consumption
of the whole seaweed group. No compounds were found
as candidate BFIs for red or green seaweeds. More work
is therefore needed to find candidate biomarkers and for
their validation before it is possible to objectively evalu-
ate the amount of seaweed consumed by humans.Additional file
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